U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Deyo R, Devine B, et al. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Sep. (Evidence Reports/Technology Assessments, No. 218.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain

The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain.

Show details

References

1.
International Association for the Study of Pain. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986;3:S1–226. [PubMed: 3461421]
2.
Institute of Medicine (U.S.) Committee on Advancing Pain Research Care and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press; Washington, DC: 2011. [PubMed: 22553896]
3.
Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: A review of the evidence. Clinical J Pain. 2008;24(6):469–78. [PubMed: 18574357]
4.
Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1-2):172–9. [PubMed: 16842922]
5.
Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: The TROUP study. Pain. 2008;138(2):440–9. [PMC free article: PMC2668925] [PubMed: 18547726]
6.
Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75. [PMC free article: PMC3280087] [PubMed: 19718704]
7.
Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225–35. [PubMed: 16618466]
8.
Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010(11):CD006605. [PMC free article: PMC6494200] [PubMed: 20091598] [CrossRef]
9.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30. [PMC free article: PMC4043401] [PubMed: 19187889]
10.
Starrels JL, Becker WC, Weiner MG, et al. Low use of opioid risk reduction strategies in primary care even for high-risk patients with chronic pain. J Gen Intern Med. 2011;26(9):958–64. [PMC free article: PMC3157518] [PubMed: 21347877]
11.
Deyo RA, Smith DH, Johnson ES, et al. Prescription opioids for back pain and use of medications for erectile dysfunction. Spine. 2013;38(11):909–15. [PMC free article: PMC3651746] [PubMed: 23459134]
12.
Substance Abuse and Mental Health Services Administration. National Admissions to Substance Abuse Treatment Services. Substance Abuse and Mental Health Services Administration; Rockville, MD: 2011. Treatment Episode Data Set (TEDS). 1999 - 2009. (DASIS Series: S-56).
13.
Substance Abuse and Mental Health Services Administration. The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Center for Behavioral Health Statistics and Quality; Rockville, MD: 2012. [PubMed: 27631059]
14.
Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712–20. [PubMed: 20513829]
15.
Warner M, Chen LH, Makuc DM, et al. Drug poisoning deaths in the United States, 1980–2008. NCHS Data Brief. 2011;81:1–8. [PubMed: 22617462]
16.
Bohnert ASB VM, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21. [PubMed: 21467284]
17.
Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA. 2011;305(13):1346–7. [PubMed: 21467287]
18.
Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25(4):310–5. [PMC free article: PMC2842546] [PubMed: 20049546]
19.
Rolita L, Spegman A, Tang X, et al. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc. 2013;61(3):335–40. [PMC free article: PMC3719174] [PubMed: 23452054]
20.
Gomes T, Redelmeier DA, Juurlink DN, et al. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med. 2013;173(3):196–201. [PubMed: 23318919]
21.
Centers for Disease Control and Prevention. Prescription Drug Overdose in the United States: Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2014. [July 17, 2014]. Available at: http://www​.cdc.gov/homeandrecreationalsafety/overdose/facts​.html.
22.
Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–94. [PMC free article: PMC1459894] [PubMed: 16717269]
23.
Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84. [PubMed: 14622741]
24.
Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36. [PubMed: 17936076]
25.
Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570–87. [PubMed: 16508405]
26.
Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147–59. [PubMed: 19187891]
27.
Furlan AD, Reardon R, Weppler C, et al. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ. 2011;182(9):923–30. [PMC free article: PMC2882451] [PubMed: 20439443]
28.
United States Department of Veterans Affairs, The Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. 2010. [September 19, 2014]. Available at: http://www​.healthquality​.va.gov/Chronic_Opioid_Therapy_COT​.asp.
29.
American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain: Evidence Review. 2009. [September 19, 2014]. Available at: http://www​.americanpainsociety​.org/uploads​/pdfs/Opioid_Final_Evidence_Report.pdf. [PMC free article: PMC4043401] [PubMed: 19187889]
30.
Owens D, Lohr KN, Atkins D, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
31.
Chou R. The effectiveness and risks of long-term opioid treatment of chronic pain. PROSPERO 2014:CRD42014007016. [September 19, 2014]. Available at: http://www​.crd.york.ac​.uk/PROSPERO/display_record​.asp?ID=CRD42014007016.
32.
U.S. Food and Drug Administration. Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) a single shared system - Current Application Holders. 2014. [September 19, 2014]. Available at: http://www​.fda.gov/downloads​/Drugs/DrugSafety​/InformationbyDrugClass/UCM348818​.pdf.
33.
Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613–20. [PubMed: 19066381]
34.
Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309(6948):188. [PMC free article: PMC2540706] [PubMed: 8044101]
35.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77. [PubMed: 8472349]
36.
Furlan AD, Pennick V, Bombardier C, et al. 2009 updated methods guidelines for systematic reviews in the Cochrane Back Review Group. Spine. 2009;24:1929–41. [PubMed: 19680101]
37.
U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. Jul, 2008. [September 19, 2014]. AHRQ Publication No. 08-05118-EF. Available at: http://www​.uspreventiveservicestaskforce​.org/uspstf08/methods/procmanual.htm.
38.
Quality AfHRa. Methods Guide for Medical Test Reviews. Rockville, MD: 2010. [September 19, 2014]. Avaiable at: http://www​.effectivehealthcare​.ahrq.gov/tasks​/sites/ehc/assets​/File/methods_guide_for_medical_tests​.pdf.
39.
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: A revised tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med. 2011;155(8):529–36. [PubMed: 22007046]
40.
McGinn TG, Guyatt GH, Wyer PC, et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. JAMA. 2000;284(1):79–84. [PubMed: 10872017]
41.
Agency for Healthcare Research and Quality. Methods guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Nov, 2013. [September 19, 2014]. AHRQ Publication No. 10(13)-EHC063-EF. Chapters available at: www​.effectivehealthcare.ahrq.gov.
42.
Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64(11):1198–207. [PubMed: 21463926]
43.
Allan L, Richarz U, Simpson K, et al. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005;30(22):2484–90. [PubMed: 16284584]
44.
Furlan A, Chaparro LE, Irvin E, et al. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag. 2011;16(5):337–51. [PMC free article: PMC3206784] [PubMed: 22059206]
45.
Noble M, Tregear SJ, Treadwell JR, et al. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manag. 2008;35(2):214–28. [PubMed: 18178367]
46.
Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116–27. [PubMed: 17227935]
47.
Carrington Reid M, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173–9. [PMC free article: PMC1495018] [PubMed: 11929502]
48.
Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain. Clin J Pain. 2014;30(7):557–64. [PMC free article: PMC4032801] [PubMed: 24281273]
49.
Banta-Green CJ, Merrill JO, Doyle SR, et al. Opioid use behaviors, mental health and pain--development of a typology of chronic pain patients. Drug Alcohol Depend. 2009;104(1-2):34–42. [PMC free article: PMC2716214] [PubMed: 19473786]
50.
Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large U.S. health-care system. Addiction. 2010;105(10):1776–82. [PubMed: 20712819]
51.
Compton PA, Wu SM, Schieffer B, et al. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008;36(4):383–95. [PMC free article: PMC2630195] [PubMed: 18508231]
52.
Cowan DT, Wilson-Barnett J, Griffiths P, et al. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003;4(4):340–51. [PubMed: 14750910]
53.
Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–82. [PMC free article: PMC1959336] [PubMed: 17499555]
54.
Hojsted J, Nielsen PR, Guldstrand SK, et al. Classification and identification of opioid addiction in chronic pain patients. Eur J Pain. 2010;14(10):1014–20. [PubMed: 20494598]
55.
Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23(4):287–99. [PubMed: 17449988]
56.
Saffier K, Colombo C, Brown D, et al. Addiction Severity Index in a chronic pain sample receiving opioid therapy. J Subst Abuse Treat. 2007;33(3):303–11. [PMC free article: PMC2721322] [PubMed: 17376639]
57.
Schneider JP, Kirsh KL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J Opioid Manag. 2010;6(6):385–95. [PubMed: 21268999]
58.
Wasan AD, Butler SF, Budman SH, et al. Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? Clin J Pain. 2009;25(3):193–8. [PMC free article: PMC2664529] [PubMed: 19333168]
59.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fifth edition. Arlington, VA: American Psychiatric Association; 2013.
60.
Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn. 2009;119(7-8):469–77. [PubMed: 19776687]
61.
Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92. [PMC free article: PMC3000551] [PubMed: 20083827]
62.
Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80. [PubMed: 15561393]
63.
Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046–51. [PMC free article: PMC1257433] [PubMed: 16207320]
64.
Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30(2):171–84. [PubMed: 17253881]
65.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260(1):76–87. [PubMed: 16789982]
66.
Miller M, Sturmer T, Azrael D, et al. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Ger Soc. 2011;59(3):430–8. [PMC free article: PMC3371661] [PubMed: 21391934]
67.
Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–86. [PubMed: 21149754]
68.
Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76. [PubMed: 21149752]
69.
Spector W, Shaffer T, Potter DE, et al. Risk factors associated with the occurrence of fractures in U.S. nursing homes: resident and facility characteristics and prescription medications. J Am Geriatr Soc. 2007;55(3):327–33. [PubMed: 17341233]
70.
Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk. Osteoporos Int. 2009;20(4):585–97. [PubMed: 18690484]
71.
Li L, Setoguchi S, Cabral H, et al. Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Am J Epidemiol. 2013;178(4):559–69. [PubMed: 23639937]
72.
Fishbain DA, Cutler RB, Rosomoff HL, et al. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16(1):9–28. [PubMed: 14650448]
73.
Fishbain DA, Cutler RB, Rosomoff HL, et al. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manag. 2003;25(6):559–77. [PubMed: 12782437]
74.
Byas-Smith MG, Chapman SL, Reed B, et al. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain. 2005;21(4):345–52. [PubMed: 15951653]
75.
Gaertner J, Frank M, Bosse B, et al. [Oral controlled-release oxycodone for the treatment of chronic pain. Data from 4196 patients] Schmerz. 2006;20(1):61–8. [PubMed: 15926076]
76.
Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manag. 2000;19(3):200–8. [PubMed: 10760625]
77.
Sabatowski R, Schwalen S, Rettig K, et al. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manag. 2003;25(1):38–47. [PubMed: 12565187]
78.
Menefee LA, Frank ED, Crerand C, et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med. 2004;5(1):42–9. [PubMed: 14996236]
79.
Carman WJ, Su S, Cook SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011;20(7):754–62. [PubMed: 21567652]
80.
Li L, Setoguchi S, Cabral H, et al. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013;273(5):511–26. [PubMed: 23331508]
81.
Merza Z, Edwards N, Walters S, et al. Patients with chronic pain and abnormal pituitary function require investigation. The Lancet. 2003;361(9376):2203–4. [PubMed: 12842375]
82.
Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7(12):901–7. [PubMed: 17157776]
83.
Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain. 2010;26(5):374–80. [PubMed: 20473043]
84.
Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686–91. [PubMed: 21482846]
85.
Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012;13(1):87–95. [PubMed: 22026451]
86.
Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010;170(16):1425–32. [PMC free article: PMC3715046] [PubMed: 20837827]
87.
Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manag. 1999;18(4):271–9. [PubMed: 10534967]
88.
Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine. 1998;23(23):2591–600. [PubMed: 9854758]
89.
Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manag. 2003;26(5):1026–48. [PubMed: 14585554]
90.
Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26(4):862–9. [PubMed: 10229408]
91.
Gostick N, Allen J, Cranfield R, et al. A comparison of the efficacy and adverse effects of controlled-release dihydrocodeine and immediate-release dihydrocodeine in the treatment of pain in osteoarthritis and chronic back pain; Proceedings of The Edinburgh Symposium on Pain Control and Medical Education; 1989.
92.
Hale M, Speight K, Harsanyi Z, et al. Efficacy of 12 hourly controlled-release codeine compared with as required dosing of acetaminophen plus codeine in patients with chronic low back pain. Pain Res Manag. 1997;2(1):33–8.
93.
Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15(3):179–83. [PubMed: 10524470]
94.
Lloyd R, Costello F, Eves M, et al. The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextro-propoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. Curr Med Res Op. 1992;13(1):37–48. [PubMed: 1468244]
95.
Hartung DM, Middleton L, Haxby DG, et al. Rates of Adverse Events of Long-Acting Opioids in a State Medicaid Program. Ann Pharmacother. 2007;41(6):921–8. [PubMed: 17504834]
96.
Mitra F, Chowdhury S, Shelley M, et al. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med. 2013;14(1):75–83. [PubMed: 23320402]
97.
Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416–27. [PubMed: 20602712]
98.
Krebs EE, Becker WC, Zerzan J, et al. Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain. 2011;152(8):1789–95. [PubMed: 21524850]
99.
Naliboff BD, Wu SM, Schieffer B, et al. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011;12(2):288–96. [PubMed: 21111684]
100.
Portenoy RK, Messina J, Xie F, et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23(1):223–33. [PubMed: 17207304]
101.
Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(4):588–601. [PubMed: 17617282]
102.
Ashburn MA, Slevin KA, Messina J, et al. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112(3):693–702. [PubMed: 21304148]
103.
Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manag. 2011;41(2):358–66. [PubMed: 21334555]
104.
Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14(9):1332–45. [PubMed: 23855816]
105.
Cowan DT, Wilson-Barnett J, Griffiths P, et al. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med. 2005;6(2):113–21. [PubMed: 15773875]
106.
Ralphs JA, Williams AC, Richardson PH, et al. Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain. 1994;56(3):279–88. [PubMed: 8022621]
107.
Tennant FS Jr, Rawson RA. Outpatient treatment of prescription opioid dependence: comparison of two methods. Arch Intern Med. 1982;142(10):1845–7. [PubMed: 6181749]
108.
Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131–46. [PubMed: 19187890]
109.
Akbik H, Butler SF, Budman SH, et al. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manag. 2006;32(3):287–93. [PubMed: 16939853]
110.
Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–42. [PubMed: 16336480]
111.
Butler SF, Budman SH, Fernandez K, et al. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112(1-2):65–75. [PubMed: 15494186]
112.
Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–72. [PMC free article: PMC2359825] [PubMed: 18203666]
113.
Jones T, Moore T, Levy JL, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain. 2012;28(2):93–100. [PubMed: 21750461]
114.
Moore TM, Jones T, Browder JH, et al. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10(8):1426–33. [PubMed: 20021601]
115.
Franklin GM, Mai J, Turner J, et al. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012;55(4):325–31. [PubMed: 22213274]
116.
Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15(4):321–37. [PubMed: 24685458]
117.
Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014;15(4):338–65. [PubMed: 24685459]
118.
U.S. Food and Drug Administration. Public Health Advisory: Important Information for the Safe Use of Fentora (fentanyl buccal tablets). Silver Springs, MD: 2013. [May 22 2014]. Available at: http://www​.fda.gov/Drugs​/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders​/DrugSafetyInformationforHeathcareProfessionals​/PublicHealthAdvisories/ucm051273.htm.
119.
Jones T, Moore T. Preliminary data on a new opioid risk assessment measure: the Brief Risk Interview. J Opioid Manag. 2013;9(1):19–27. [PubMed: 23709300]
120.
Butler SF, Budman SH, Fanciullo GJ, et al. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain. 2010;26(9):770–6. [PMC free article: PMC2955853] [PubMed: 20842012]
121.
Butler SF, Budman SH, Fernandez KC, et al. Cross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R). J Addict Med. 2009;3(2):66–73. [PMC free article: PMC2712300] [PubMed: 20161199]
122.
Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9(8):1098–106. [PMC free article: PMC2779534] [PubMed: 18721174]
123.
Meltzer EC, Rybin D, Saitz R, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011;152(2):397–402. [PMC free article: PMC3027065] [PubMed: 21177035]
124.
Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144–56. [PMC free article: PMC1950245] [PubMed: 17493754]
125.
Holmes CP, Gatchel RJ, Adams LL, et al. An Opioid Screening Instrument: Long-Term Evaluation of the Utility of the Pain Medication Questionnaire. Pain Pract. 2006;6(2):74–88. [PubMed: 17309714]
126.
Reifler LM, Droz D, Bailey JE, et al. Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse? Pain Med. 2012;13(3):434–42. [PubMed: 22299725]
127.
Deyo RA, Smith DH, Johnson ES, et al. Opioids for back pain patients: primary care prescribing patterns and use of services. J Am Board Fam Med. 2011;24(6):717–27. [PMC free article: PMC3855548] [PubMed: 22086815]
128.
Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in us veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940–7. [PubMed: 22396516]
129.
Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166(19):2087–93. [PubMed: 17060538]
130.
Morasco BJ, Duckart JP, Carr TP, et al. Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain. Pain. 2010;151(3):625–32. [PMC free article: PMC2972371] [PubMed: 20801580]
131.
Carson S, Thakurta S, Low A, et al. Portland, OR: Jul, 2011. Drug Class Review: Long-Acting Opioid Analgesics: Final Update 6 Report Oregon Health & Science University. [PubMed: 21977550]
132.
Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444–59. [PubMed: 18489635]
133.
Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain. 2008;24(6):497–508. [PubMed: 18574359]
134.
Wiedemer NL, Harden PS, Arndt IO, et al. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8(7):573–84. [PubMed: 17883742]
135.
Goldberg KC, Simel DL, Oddone EZ. Effect of an opioid management system on opioid prescribing and unscheduled visits in a large primary care clinic. J Clin Outcome Manag. 2005;12(12)
136.
Manchikanti L, Manchukonda R, Damron KS, et al. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9(1):57–60. [PubMed: 16700282]
137.
Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123–9. [PubMed: 16703972]
138.
Pablos-Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for hte application of results in clinical practice. JAMA. 1998;279(3):222–5. [PubMed: 9438743]
139.
Furlan AD, Reardon R, Weppler C. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ. 2010;182(9):923–30. [PMC free article: PMC2882451] [PubMed: 20439443]
140.
Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47. [PMC free article: PMC6721847] [PubMed: 24217469]
141.
O'Connor AB, Turk DC, Dworkin RH, et al. Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain. 2013;154(11):2324–34. [PubMed: 24148704]
142.
Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9. [PubMed: 22784140]
143.
Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ. 1998;316:285. [PMC free article: PMC2665488] [PubMed: 9472515]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.7M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...